Seegene Inc. unveiled its next-generation molecular diagnostics platform, CURECA™, during the ESCMID Global 2025 event in Vienna, attracting strong interest from industry experts and healthcare professionals. The system was presented through a conceptual video, showcasing its capacity to fully automate the entire PCR diagnostic workflow, from primary sample handling to result analysis. More than 2,300 global attendees visited Seegene’s booth, where they previewed CURECA™ and engaged in discussions about its transformative potential. Experts highlighted the system's ability to eliminate manual processing errors and operate without time or labor constraints, making it a promising solution for a wide range of clinical settings.

A major innovation within the CURECA™ system is its Customizable Pre-treatment System (CPS),e- which automates the labor-intensive specimen preprocessing stage—especially for complex sample types like blood, stool, urine, and sputum. This modular component is designed to streamline operations not only in PCR-based diagnostics but also in clinical chemistry and immunology workflows. Professionals at ESCMID emphasized that automating preprocessing could improve turnaround time, reduce operator fatigue, and expand access to high-throughput testing in smaller laboratories. The system's intelligent software is also capable of adjusting workflows based on reporting deadlines, offering operational flexibility particularly valuable for high-priority conditions such as sexually transmitted infections (STIs).

CURECA™ is built with a modular and configurable architecture, allowing laboratories to adopt it either as a fully integrated system or in parts—such as CPS, the Primary Sample Aliquot System (PAS), or the Customizable & Expandable Full Automation (CEFA) module—depending on their space, staffing, and diagnostic needs. This flexibility was praised as a game changer by professionals seeking adaptable automation tools in constrained lab environments. Seegene's vision, supported by widespread interest at ESCMID 2025, positions CURECA™ as a potential catalyst for global transformation in PCR diagnostics, advancing both efficiency and diagnostic accuracy across diverse healthcare settings.